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Abstract
Onchocerciasis (river blindness) is a blinding parasitic disease that threatens the health of approximately 120
million people worldwide. While 99% of the population at-risk for infection from onchocerciasis live in Africa, some
500,000 people in the Americas are also threatened by infection. A relatively recent arrival to the western
hemisphere, onchocerciasis was brought to the New World through the slave trade and spread through migration.
The centuries since its arrival have seen advances in diagnosing, mapping and treating the disease. Once endemic
to six countries in the Americas (Brazil, Colombia, Ecuador, Guatemala, Mexico and Venezuela), onchocerciasis is on
track for interruption of transmission in the Americas by 2012, in line with Pan American Health Organization
resolution CD48.R12. The success of this public health program is due to a robust public-private partnership
involving national governments, local communities, donor organizations, intergovernmental bodies, academic
institutions, non-profit organizations and the pharmaceutical industry. The lessons learned through the efforts in
the Americas are in turn informing the program to control and eliminate onchocerciasis in Africa. However,
continued support and investment are needed for program implementation and post-treatment surveillance to
protect the gains to-date and ensure complete elimination is achieved and treatment can be safely stopped within
all 13 regional foci.
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Introduction
Onchocerciasis is a tropical disease caused by the parasite
Onchocerca volvulus, which is transmitted by the black
fly. The Simulium f l i e st h a tt r a n s m i to n c h o c e r c i a s i s
breed in fast-flowing rivers, giving rise to the common
name “river blindness” for the disease. Once transmitted
to a human host, L3 infective-stage larvae molt twice and
mature into adult worms within nodules underneath the
skin, commonly in the midsection and around the head.
The adult worms inside reproduce, creating millions of
larvae (microfilariae) that move under the skin and cause
intense itching, skin lesions and loss of pigmentation, as
well as penetrating the eye causing sight impairment and
eventual blindness.
Worldwide there are more than 120 million people at
risk of contracting the disease, with some 18 million
people infected. More than 99% of the disease burden is
in Africa. In the Americas, about 500,000 people have
historically been at risk of infection in 13 foci throughout
Brazil, Colombia, Ecuador, Guatemala, Mexico and
Venezuela.
An Imported Infection
Onchocerciasis arrived in the Americas through the slave
trade. Starting in the early 16
th century, slaves from the
heavily endemic areas of West Africa were brought to
Central and South America, bringing with them O. volvu-
lus parasites. Slaves then migrated within the colonies,
including between coffee plantations, carrying with them
the parasites with which they were infected. Not being
confined to the original African hosts, and as suitable
Simulium species were present, the parasites were also
transmitted to the indigenous American population and
then spread further through migration, including among
certain contiguous border countries like Guatemala and
Mexico [1]. The spread of the disease through labor and
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the environment, explains the presence of onchocerciasis
in Ecuador, Colombia, Guatemala, Mexico and Northern
Venezuela [2], and genetic testing of parasites confirms
this linkage between Old World and New World
O. volvulus [3].
H o w e v e r ,o n eo p e nq u e s t i o ni st h em a n n e ri nw h i c h
onchocerciasis has spread to the Amazon region in the
border area between Brazil and Venezuela. This area is
extremely isolated, is not part of the coffee growing region
and is not part of common trade routes, either now or his-
torically. One theory is that the geographic area which the
Amazonian people groups once inhabited was much more
extensive in the past, encompassing areas where there was
once sufficient contact for onchocerciasis transmission to
occur from slave to native populations. In the years follow-
ing that exposure, however, these people groups moved
into more isolated regions that had no outside contact and
thus brought onchocerciasis into this isolated, interior
area. Another theory is that it came through movement of
indigenous populations from other foci from the North of
Venezuela [4].
Although the slave trade brought onchocerciasis to the
Americas, Simulium damnosum, the most common vec-
tor that transmits O. volvulus in West Africa, is not
found in the Americas. Instead, onchocerciasis in the
Northern part of the Americas, Guatemala and Mexico,
is primarily transmitted by S. ochraceum, which is con-
sidered less efficient than S. damnosum at transmitting
O. volvulus. On the other hand, disease is transmitted in
the southern part, namely Brazil, Colombia, Ecuador,
and Southern Venezuela, by S. exiguum and S. guia-
nense, which are both considered as efficient as S. dam-
nosum. All of them, however, do not cover extensive
geographical areas. As a result, onchocerciasis exists in
the Americas only in circumscribed areas that are rela-
tively small and isolated. From a public health stand-
point, this means that onchocerciasis in the Americas
has been easier to track, map and treat, and less likely
to spread, than it is in Africa. In addition, the treatment
strategy adopted by OEPA for the Americas involves
mass drug administration to all the eligible population
at least twice per year, versus once a year as it is done
in Africa.
Given the impact of onchocerciasis in the Americas it
is no surprise that there was critical early scientific
investigation into the disease conducted by a researcher
from an affected country. A physician from Guatemala,
Dr. Rodolfo Robles (1878-1939), conducted studies on
patients with onchocerciasis, which led to the discovery
in 1915 that the disease is caused by O. volvulus.I n
honor of this important research contribution, oncho-
cerciasis is also called ‘Robles Disease’ [5].
Treatment Options
There have been various treatment approaches to control
the disease in individual patients and at the community
level in the Americas. Surgical removal of the subcuta-
neous nodules that contain the adult parasites was con-
ducted mainly in the past. However, not all nodules are
easily visible and palpable since some of them are deeper
in the tissue, making removal difficult and frequently
missed, and also removal, when possible, is painful to the
patient. As a result, surgical control of onchocerciasis is
difficult to conduct on a large-scale, community level.
The first pharmaceutical treatments used were diethyl-
carbamazine (DEC) and suramin. However, treatment
with these two drugs can create serious side effects,
including blindness in patients with advanced onchocer-
cal eye disease and renal failure in the case of suramin,
making them unattractive treatment options, especially
for wide-scale use at a community level [6]. Vector con-
trol, through the use of insecticides to control the black
fly population, has also been used with some success on a
local level [7]. The current MDA treatment approach,
initiated in the late 1980s following the discovery and
development of MECTIZAN (ivermectin) by the pharma-
ceutical company Merck (known outside the United
States and Canada as MSD), has offered the opportunity
for disease control and elimination.
The River Blindness Partnership
In 1987 Merck announced its decision to donate MECTI-
ZAN - “as much as necessary for as long as necessary” -
through the MECTIZAN Donation Program. In support
of this commitment a global partnership developed invol-
ving the MECTIZAN Expert Committee, local commu-
nities affected by onchocerciasis, local and international
non-profit organizations, national governments and their
ministries of health, the World Health Organization, and
the World Bank [8].
In the Americas, the effort to eliminate onchocerciasis is
carried out through a broad range of partners under the
general coordination of the Onchocerciasis Elimination
Program for the Americas (OEPA). Led and supported by
the Carter Center, OEPA - headquartered in Guatemala -
is notable for the ongoing, direct involvement of ministries
of health from the six affected countries. The OEPA part-
nership involves financial and technical support through
the Bill & Melinda Gates Foundation, the US Centers for
Disease Control and Prevention, the Lions Clubs Interna-
tional Foundation, the Pan American Health Organization
and others. The various members of the partnership
engage on key issues such as overall organization and
alignment of roles, advocacy, financial support and drug
donations, support for operational and technical research,
education, and communications [9].
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Through ongoing feedback between field programs and
other members of the partnership, in Africa and the
Americas, various operational and technical efficiencies
have been incorporated over the past two decades. For
example, the packaging of MECTIZAN was changed from
an individually packed foil strip to a 500-count bottle,
allowing for simpler distribution to communities and less
waste. The MECTIZAN tablet size was reduced from
6 mg to 3 mg, enabling more accurate and simple dosing
at the field level without the need to split the tablet for
those requiring a 3 mg or 9 mg dose. The determination
of the proper dose for each treatment is now determined
by height rather than weight, making use of a low-tech
measuring stick instead of a bulky and unwieldy scale [10].
Also in 2003, Merck authorized treatment in children by
t h eu s eo fe i t h e ro n eo ft h et h r e ec r i t e r i an o r m a l l y
required: weight, height and/or age, which provided the
opportunity to increase the number of eligible children
receiving treatment. Early in the program the treatment
frequency strategy in the Americas was established to be
twice annually after it was demonstrated that this would
have an accelerating effect on stopping disease transmis-
sion [11]. These improvements, in addition to the fact that
the MDA approach is offered at least twice each year to all
eligible individuals living in all endemic communities with
the goal of reaching a minimum of 85% treatment cover-
age, have all supported the advancement of the program
objective in the Americas from one of simply controlling
onchocerciasis, to one of completely eliminating transmis-
sion of the disease.
Consensus for Action
Further galvanizing the resolve of the partners to elimi-
nate onchocerciasis from the Americas was a resolution
by the Pan American Health Organization (PAHO) in
1991, calling for the elimination of onchocerciasis mor-
bidity from the Americas by 2007 [12]. PAHO Resolution
XIV served as an effective advocacy platform, providing
the springboard from which OEPA was launched in
1992. The main goal of Resolution XIV was attained in
most, but not all, of the 13 foci by 2007, providing much
needed regional attention on the public health opportu-
nity of onchocerciasis elimination. One country, Colom-
bia (with its single focus, Lopez de Micay), did in fact
achieve the goal of interrupting transmission of oncho-
cerciasis in 2007, serving as a proof of concept (See
Figure 1).
Recognizing the ongoing potential for complete elimi-
nation of onchocerciasis in the Americas region, PAHO
Directing Council approved a new resolution in 2008
(CD48.R12). The goal of this resolution is three-fold: (1)
to complete elimination of new onchocerciasis-related
eye disease in all foci by 2012; (2) to interrupt
onchocerciasis transmission in the 13 foci by 2012 (the
last year for the distribution of treatment); (3) to
complete the required three-year post-treatment epide-
miological surveillance phase following WHO’s criteria
and procedures for certification of elimination of human
Onchocerciasis by 2015 [13]. Suppression of transmission
occurs when the population is no longer exposed to L3
infective-stage larvae through vector transmission, but
treatment continues. Areas characterized as having inter-
rupted transmission have achieved negative PCR (Poly-
merase Chain Reaction) in flies and negative OV16
antibody tests in young children, and where treatment
has been suspended. Following a 3-year surveillance per-
iod, an ongoing negative PCR result indicates elimination
of transmission [14].
Already, a peak has been reached in the number of
treatments of MECTIZAN distributed in the Americas as
individual foci reach endpoints of suspected interruption
of transmission of onchocerciasis. Total treatments on a
regional level reached a peak in 2003-2006 and are fore-
cast to stop entirely in 2013 (see Figure 2). At the end of
2010, both Colombia and Ecuador had interrupted trans-
mission and completely stopped ivermectin treatment on
a national level and are undergoing the required post-
treatment surveillance to confirm disease elimination in
order to request certification by the World Health Orga-
nization. Certification for Colombia is expected at the
end of 2011 or early 2012; Ecuador will be eligible by
2013. At a sub-national level, several formerly endemic
areas in Mexico, Guatemala and Venezuela have also
stopped treatment but will have to wait until all foci
within each given country become ready, since according
to WHO’s criteria, only entire countries can request final
certification. However, the Yanomami area on the Brazil-
Venezuela border is considered the greatest challenge to
meeting the ambitious goal set by Resolution CD48.R12
[14].
Continued attention to operational elements of the
river blindness program in the Americas is highly neces-
sary in order to achieve and maintain the elimination of
transmission, which would allow for permanent suspen-
sion of treatment with MECTIZAN.
The most basic objective is for the remaining areas
undergoing treatment with MECTIZAN to maintain high
coverage - greater than 85% of the total population at-
risk - for their bi-annual treatments, with treatment
increased to 4 times per year in some areas where neces-
sary and feasible to accelerate the transmission interrup-
tion process [7,14]. While the 85% threshold has now
been reached in all foci still under treatment [14], main-
taining high coverage will be especially important in the
endemic area of the Amazon region (Yanomami area) on
the border shared by Brazil and Venezuela. The geogra-
phically hard to reach location of the affected area
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1. Oaxaca
44,919
3. South 
Chiapas
109,617
2. North Chiapas
7,125 
4. Huehuetenango
30,239 
5. Central
121,751
7. Santa Rosa
12,208 
6. Escuintla
62,590
12. Lopez de Micay
1,366
13. Esmeraldas
25,863
8. Northcentral
13,989
9. Northeast
93,009
10. South
8,462
11. Amazonas
11,807
Regional summary:                                     
Population at risk:  461,022
Population no longer at risk:  81,923
Population eligible for treatment:  326,253
Population under Post Treatment Surveillance:   116,376
ELIMINATED
SUPPRESSED
Transmission Status
ONGOING
INTERRUPTED
15%
43%
Pop. %
21%
21%
Figure 1 Geographic distribution and transmission status of the 13 onchocerciasis foci in the Americas as of December, 2010.
Figure 2 History of MECTIZAN treatment in the Americas and projection from 2011 - 2015. In 1995 all foci initiated 2x/year treatment. The
annual peak of aggregate treatments for the region was reached in 2005. If the goals of PAHO resolution CD48.R12 are achieved, 2012 will be the
final year that onchocerciasis treatment will be necessary, with all countries eligible for WHO certification of elimination no later than 2016.
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make it especially difficult to maintain regular treat-
ments. In some cases, use of an alternate therapy, such as
the antibiotic doxycycline as an end-game approach, may
be necessary to ensure full elimination of infection and
transmission. The use of doxycycline in onchocerciasis
control programs has been demonstrated in the African
setting [15].
Other critical issues remain that must be addressed in
order to maintain the momentum towards successful
onchocerciasis elimination. Populations at-risk must
continue to be accurately counted and located, to ensure
sustained treatment coverage rates in the remaining
areas of transmission of the disease. People living in
endemic areas must continue to participate in educa-
tional programs in order to understand issues relating
to stopping treatment and the surveillance necessary to
help identify potential recrudescence. There must be
support for post-treatment surveillance and evaluations
once treatment has been suspended in order to ensure
and confirm transmission elimination. To accomplish
this, new or improved diagnostic tools need to be devel-
oped and made available. Concerted attention to these
issues by all partners, with the critical backing of
expanded political will and financial support from gov-
ernments in affected countries, is necessary to maintain
the momentum and assure completion of this public
health program [16].
Adios, onchocerciasis
Certification by the World Health Organization of the
elimination of onchocerciasis in Colombia in late 2011
or early 2012 would serve as a test case for both the
operational approach taken to reach the point of elimi-
nation, and for the method by which elimination is cer-
tified. If the initiative proves successful on a regional
level, it would represent a true international public
health triumph – the end of nearly half a millennium of
onchocerciasis in the Western Hemisphere. More than
half a million people would be forever free from the
threat of contracting this debilitating and blinding dis-
ease. Moreover, the elimination of onchocerciasis carries
with it significant social and economic benefits for the
formerly affected individuals, communities, and
countries.
In a fitting historical counterpoint, the lessons learned
through the elimination of onchocerciasis in the Ameri-
cas can be applied to the African setting. Although the
challenges of onchocerciasis elimination are more
daunting in Africa due to the size of the affected popu-
lation and the vast geographic extent of the disease,
recent studies suggest the feasibility of elimination in
some areas using current treatment tools [17].
Conclusions
Onchocerciasis has been a public health threat in the
Americas for nearly five centuries, impacting hundreds of
thousands of people with the threat of severe dermatologi-
cal conditions, vision impairment and blindness. However,
advances in pharmaceutical therapy and innovative
approaches to public health developed by various stake-
holders have established an effective approach to addres-
sing the disease on individual, community, national and
regional levels. As a result of continued and focused
investment from a range of contributors, including gov-
ernment, non-profit, scientific and industry bodies, there
is very real potential for elimination of onchocerciasis
from the Western Hemisphere within the next few years.
Such an accomplishment would hold tremendous public
health value for the region as well as offer valuable lessons
learned for other geographic areas where onchocerciasis
continues to be a health burden.
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